Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 104 matching trials from the live ClinicalTrials.gov search.
Conditions
Contraception
Interventions
Subcutaneous depot medroxyprogesterone acetate
Drug
Lead sponsor
Planned Parenthood Federation of America
Other
Eligibility
15 Years to 44 Years · Female only
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Morristown, New Jersey • Houston, Texas
Conditions
IUD, Contraceptive Implant, Contraception, Birth Control, Emergency Contraception
Interventions
Copper T-380 IUD, LNG IUD, Contraceptive implant Nexplanon, Depo-Provera
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
West Valley City, Utah
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women

NCT03018366
Conditions
Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
Interventions
17beta Estradiol, Transdermal placebo patch, Progesterone, Placebo Pill
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

PK of Depo SubQ Injected in the Upper Arm

NCT01143207
Conditions
Contraception
Interventions
Medroxyprogesterone acetate
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Menorrhagia
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
37
States / cities
Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more
Conditions
Endometrial Hyperplasia
Interventions
BAY865028, Medroxyprogesterone acetate
Combination Product · Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more
Conditions
Advanced, Persistent, or Recurrent Endometrial Cancer
Interventions
Everolimus, Tamoxifen, Letrozole, Medroxyprogesterone Acetate
Drug
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
26
States / cities
Aurora, Colorado • Miami, Florida • Columbus, Georgia + 21 more
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate, Efavirenz, Nevirapine, Medroxyprogesterone acetate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 17 more
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

HSG and Tubal Patency Study

NCT02146248
Conditions
Tubal Patency
Interventions
combined oral contraceptive, DepoProvera
Drug
Lead sponsor
Jeffrey Jensen
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Opiate Addiction, Pregnancy, Contraceptive Behavior, Sexual Behavior
Interventions
Nexplanon (etonogestrel contraceptive implant), Standard postpartum contraceptive care
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 2 Interventional Results available

Estrogen Receptor Beta and Mood

NCT03689543
Conditions
Perimenopause-Related Depression
Interventions
Estradiol, ER Beta Agonist, Placebo, Provera
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
45 Years to 65 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Polycystic Ovarian Syndrome, Vitamin D Deficiency
Interventions
Vitamin D2 (Ergocalciferol), Medroxyprogesterone (Provera), Vitamin D3 (Cholecalciferol), Elemental Calcium
Dietary Supplement · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects

NCT01461824
Conditions
Weight Gain, Disorder of Bone Density and Structure, Unspecified, Uterine Bleeding
Interventions
Depot medroxyprogesterone acetate (DMPA)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Anorexia Nervosa on Bone Mass in Adolescents

NCT00088153
Conditions
Anorexia Nervosa
Interventions
Physiologic Estrogen/progesterone, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV-1 Infection
Interventions
depo-medroxyprogesterone acetate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 7 more
Conditions
Healthy
Interventions
IM Saline Placebo (0.25 ml), IM Estradiol valerate (2.5 mg), IM Saline Placebo (0.5 ml), IM Estradiol valerate (5.0 mg), Oral Micronized Progesterone, Oral Placebo, Ghrelin (0.3 ug/kg), Medroxyprogesterone - Acetate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Infertility (IVF Patients)
Interventions
Opt-IVF, Control
Combination Product · Other
Lead sponsor
Urmila DIwekar
Industry
Eligibility
20 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Impact of Contraception on Postpartum Weight Loss

NCT02144259
Conditions
Weight
Interventions
DMPA immediately postpartum, Implanon immediately postpartum
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Coronary Heart Disease
Interventions
Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
2,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
San Francisco, California
Terminated No phase listed Observational Accepts healthy volunteers

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

NCT01750476
Conditions
Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
Interventions
Mirena, Oral contraception, Depo-Provera
Drug
Lead sponsor
Thomas Cherpes, DVM, MD
Other
Eligibility
15 Years to 25 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Polycystic Ovarian Syndrome
Interventions
Raloxifene, Clomiphene
Drug
Lead sponsor
Bruce Lessey
Other
Eligibility
18 Years to 36 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, South Carolina
Conditions
Alzheimer Disease
Interventions
Transdermal estradiol, Medroxyprogesterone, Placebo Patch, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 90 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 2 Interventional Results available

Research Investigation of Soy and Estrogen

NCT00997893
Conditions
Menopause, Hot Flashes
Interventions
Soy Phytoestrogen, Estradiol, Medroxyprogesterone Acetate (MPA), Soy Placebo, MPA Placebo
Dietary Supplement · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois